Axogen stock hits 52-week high at 51.13 USD

Axogen Inc's stock has reached a 52-week high of 51.13 USD, marking a significant increase of 214.19% over the past year. The medical device company, with a market capitalization of 2.73 billion USD, reported a 23% revenue growth in Q2 2026, reaching $69.7 million, which surpassed Wall Street's estimate of $67.1 million. Despite posting a net loss of $1.5 million, Axogen's strong financial performance has caught the attention of several analysts, with H.C.

Wainwright raising its price target to $53, maintaining a Buy rating, and Citizens increasing its target to $55. Truist Securities also initiated coverage on Axogen with a Buy rating and a price target of $60, acknowledging the company's growth potential in the peripheral nerve repair market.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.